Literature DB >> 8836495

Duchenne/Becker muscular dystrophy: from molecular diagnosis to gene therapy.

M Matsuo1.   

Abstract

Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are X-linked muscular dystrophies. The recent isolation of the defective gene in DMD/BMD and the identification of its protein product, dystrophin, have revolutionized our ability to diagnose DMD/BMD and promoted speculation regarding the application of gene therapy. The purpose of this review is to present progress made in this area of research, with particular reference to dystrophin Kobe, which is caused by exon skipping during splicing due to the presence of an intra-exon deletion. On the basis of result of molecular analysis of dystrophin Kobe we propose a novel way of gene therapy for DMD, in which antisense oligonucleotides transform DMD into BMD phenotype by inducing exon skipping.

Entities:  

Mesh:

Year:  1996        PMID: 8836495     DOI: 10.1016/0387-7604(96)00007-1

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  16 in total

1.  A commentary on a novel splicing silencer generated by DMD exon 45 deletion junction could explain upstream exon 44 skipping that modifies dystrophinopathy.

Authors:  Yukitoshi Ishikawa
Journal:  J Hum Genet       Date:  2014-07-03       Impact factor: 3.172

2.  Disruption of the splicing enhancer sequence within exon 27 of the dystrophin gene by a nonsense mutation induces partial skipping of the exon and is responsible for Becker muscular dystrophy.

Authors:  N Shiga; Y Takeshima; H Sakamoto; K Inoue; Y Yokota; M Yokoyama; M Matsuo
Journal:  J Clin Invest       Date:  1997-11-01       Impact factor: 14.808

Review 3.  Isolated and contiguous glycerol kinase gene disorders: a review.

Authors:  D R Sjarif; J K Ploos van Amstel; M Duran; F A Beemer; B T Poll-The
Journal:  J Inherit Metab Dis       Date:  2000-09       Impact factor: 4.982

4.  Low incidence of limb-girdle muscular dystrophy type 2C revealed by a mutation study in Japanese patients clinically diagnosed with DMD.

Authors:  Yo Okizuka; Yasuhiro Takeshima; Kyoko Itoh; Zhujun Zhang; Hiroyuki Awano; Koichi Maruyama; Toshiyuki Kumagai; Mariko Yagi; Masafumi Matsuo
Journal:  BMC Med Genet       Date:  2010-03-30       Impact factor: 2.103

5.  Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping.

Authors:  Adeline Vulin; Inès Barthélémy; Aurélie Goyenvalle; Jean-Laurent Thibaud; Cyriaque Beley; Graziella Griffith; Rachid Benchaouir; Maëva le Hir; Yves Unterfinger; Stéphanie Lorain; Patrick Dreyfus; Thomas Voit; Pierre Carlier; Stéphane Blot; Luis Garcia
Journal:  Mol Ther       Date:  2012-09-11       Impact factor: 11.454

6.  Red-green color vision impairment in Duchenne muscular dystrophy.

Authors:  Marcelo Fernandes Costa; Andre Gustavo Fernandes Oliveira; Claudia Feitosa-Santana; Mayana Zatz; Dora Fix Ventura
Journal:  Am J Hum Genet       Date:  2007-04-13       Impact factor: 11.025

7.  Chemical treatment enhances skipping of a mutated exon in the dystrophin gene.

Authors:  Atsushi Nishida; Naoyuki Kataoka; Yasuhiro Takeshima; Mariko Yagi; Hiroyuki Awano; Mitsunori Ota; Kyoko Itoh; Masatoshi Hagiwara; Masafumi Matsuo
Journal:  Nat Commun       Date:  2011       Impact factor: 14.919

8.  Dynamics of co-transcriptional pre-mRNA folding influences the induction of dystrophin exon skipping by antisense oligonucleotides.

Authors:  Keng Boon Wee; Zacharias Aloysius Dwi Pramono; Jian Li Wang; Karl F MacDorman; Poh San Lai; Woon Chee Yee
Journal:  PLoS One       Date:  2008-03-26       Impact factor: 3.240

9.  Lamin A/C-mediated neuromuscular junction defects in Emery-Dreifuss muscular dystrophy.

Authors:  Alexandre Méjat; Valérie Decostre; Juan Li; Laure Renou; Akanchha Kesari; Daniel Hantaï; Colin L Stewart; Xiao Xiao; Eric Hoffman; Gisèle Bonne; Tom Misteli
Journal:  J Cell Biol       Date:  2009-01-05       Impact factor: 10.539

10.  Antisense oligonucleotide induced exon skipping and the dystrophin gene transcript: cocktails and chemistries.

Authors:  Abbie M Adams; Penny L Harding; Patrick L Iversen; Catherine Coleman; Sue Fletcher; Steve D Wilton
Journal:  BMC Mol Biol       Date:  2007-07-02       Impact factor: 2.946

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.